Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response

Read full release

First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients

Read full release

TILT Biotherapeutics secures over EUR 6 million to advance cancer immunotherapies into clinic

Read full release

IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

Read full release

BC Platforms and Kaiser Permanente Win 2020 Microsoft Health Innovation Award for Precision Medicine Collaboration

Read full release